Sanjay Kaul

Summary

Affiliation: Cedars-Sinai Medical Center
Country: USA

Publications

  1. ncbi request reprint Rosiglitazone and cardiovascular risk
    Sanjay Kaul
    Division of Cardiology, Cedars Sinai Medical Center, 8700 Beverly Boulevard, Los Angeles, CA 90048, USA
    Curr Atheroscler Rep 10:398-404. 2008
  2. ncbi request reprint ApoA-I Milano/phospholipid complexes emerging pharmacological strategies and medications for the prevention of atherosclerotic plaque progression
    Sanjay Kaul
    Vascular Physiology and Thrombosis Research Laboratory of the Atherosclerosis Research Center, Division of Cardiology, Cedars Sinai Medical Center, Los Angeles, California, USA
    Curr Drug Targets Cardiovasc Haematol Disord 5:471-9. 2005
  3. ncbi request reprint Making sense of noninferiority: a clinical and statistical perspective on its application to cardiovascular clinical trials
    Sanjay Kaul
    Division of Cardiology, Cedars Sinai Medical Center, David Geffen School of Medicine, University of California, Los Angeles, CA 90048, USA
    Prog Cardiovasc Dis 49:284-99. 2007
  4. ncbi request reprint Intramural delivery of recombinant apolipoprotein A-IMilano/phospholipid complex (ETC-216) inhibits in-stent stenosis in porcine coronary arteries
    Sanjay Kaul
    Vascular Physiology and Thrombosis Research Laboratory of the Atherosclerosis Research Center, Cedars Sinai Medical Center, Los Angeles, Calif 90048, USA
    Circulation 107:2551-4. 2003
  5. doi request reprint Trial and error. How to avoid commonly encountered limitations of published clinical trials
    Sanjay Kaul
    Division of Cardiology, Cedars Sinai Medical Center, and the David Geffen School of Medicine, University of California, Los Angeles, California 90048 1804, USA
    J Am Coll Cardiol 55:415-27. 2010
  6. ncbi request reprint Homocysteine hypothesis for atherothrombotic cardiovascular disease: not validated
    Sanjay Kaul
    Division of Cardiology, Cedars Sinai Medical Center, University of California, Los Angeles, California 90048, USA
    J Am Coll Cardiol 48:914-23. 2006
  7. ncbi request reprint Current status and future trends in drug-eluting stents
    Sanjay Kaul
    Division of Cardiology, Cedars Sinai Medical Center and the David Geffen School of Medicine, University of California, Los Angeles, CA 90048, USA
    Am Heart Hosp J 5:165-8. 2007
  8. ncbi request reprint Good enough: a primer on the analysis and interpretation of noninferiority trials
    Sanjay Kaul
    Division of Cardiology, Cedars Sinai Medical Center and David Geffen School of Medicine, University of California, Los Angeles, California 90048, USA
    Ann Intern Med 145:62-9. 2006
  9. ncbi request reprint Rapid reversal of endothelial dysfunction in hypercholesterolemic apolipoprotein E-null mice by recombinant apolipoprotein A-I(Milano)-phospholipid complex
    Sanjay Kaul
    Vascular Physiology and Thrombosis Research Laboratory of the Atherosclerosis Research Center, Division of Cardiology, Cedars Sinai Medical Center, Los Angeles, California 90048, USA
    J Am Coll Cardiol 44:1311-9. 2004
  10. ncbi request reprint Trials and tribulations of non-inferiority: the ximelagatran experience
    Sanjay Kaul
    Division of Cardiology, Cedars Sinai Medical Center, and the David Geffen School of Medicine, University of California, Los Angeles, California 90048, USA
    J Am Coll Cardiol 46:1986-95. 2005

Detail Information

Publications59

  1. ncbi request reprint Rosiglitazone and cardiovascular risk
    Sanjay Kaul
    Division of Cardiology, Cedars Sinai Medical Center, 8700 Beverly Boulevard, Los Angeles, CA 90048, USA
    Curr Atheroscler Rep 10:398-404. 2008
    ..We conclude that the data showing the increased risk for myocardial infarction and death from cardiovascular disease for diabetic patients taking rosiglitazone are inconclusive...
  2. ncbi request reprint ApoA-I Milano/phospholipid complexes emerging pharmacological strategies and medications for the prevention of atherosclerotic plaque progression
    Sanjay Kaul
    Vascular Physiology and Thrombosis Research Laboratory of the Atherosclerosis Research Center, Division of Cardiology, Cedars Sinai Medical Center, Los Angeles, California, USA
    Curr Drug Targets Cardiovasc Haematol Disord 5:471-9. 2005
    ..These promising data provide the rationale for the development of reconstituted HDL utilizing recombinant apoA-IM as a potential therapeutic approach for atherothrombotic vascular disease in humans...
  3. ncbi request reprint Making sense of noninferiority: a clinical and statistical perspective on its application to cardiovascular clinical trials
    Sanjay Kaul
    Division of Cardiology, Cedars Sinai Medical Center, David Geffen School of Medicine, University of California, Los Angeles, CA 90048, USA
    Prog Cardiovasc Dis 49:284-99. 2007
    ....
  4. ncbi request reprint Intramural delivery of recombinant apolipoprotein A-IMilano/phospholipid complex (ETC-216) inhibits in-stent stenosis in porcine coronary arteries
    Sanjay Kaul
    Vascular Physiology and Thrombosis Research Laboratory of the Atherosclerosis Research Center, Cedars Sinai Medical Center, Los Angeles, Calif 90048, USA
    Circulation 107:2551-4. 2003
    ....
  5. doi request reprint Trial and error. How to avoid commonly encountered limitations of published clinical trials
    Sanjay Kaul
    Division of Cardiology, Cedars Sinai Medical Center, and the David Geffen School of Medicine, University of California, Los Angeles, California 90048 1804, USA
    J Am Coll Cardiol 55:415-27. 2010
    ..Accordingly, this review highlights these limitations using numerous examples of published clinical trials and describes ways to overcome these limitations, thereby improving the interpretability of research findings...
  6. ncbi request reprint Homocysteine hypothesis for atherothrombotic cardiovascular disease: not validated
    Sanjay Kaul
    Division of Cardiology, Cedars Sinai Medical Center, University of California, Los Angeles, California 90048, USA
    J Am Coll Cardiol 48:914-23. 2006
    ..This review outlines the metabolism and pathophysiology of homocysteine, highlights the results of homocysteine observational and interventional trials, and presents areas of uncertainty and potential future work...
  7. ncbi request reprint Current status and future trends in drug-eluting stents
    Sanjay Kaul
    Division of Cardiology, Cedars Sinai Medical Center and the David Geffen School of Medicine, University of California, Los Angeles, CA 90048, USA
    Am Heart Hosp J 5:165-8. 2007
  8. ncbi request reprint Good enough: a primer on the analysis and interpretation of noninferiority trials
    Sanjay Kaul
    Division of Cardiology, Cedars Sinai Medical Center and David Geffen School of Medicine, University of California, Los Angeles, California 90048, USA
    Ann Intern Med 145:62-9. 2006
    ....
  9. ncbi request reprint Rapid reversal of endothelial dysfunction in hypercholesterolemic apolipoprotein E-null mice by recombinant apolipoprotein A-I(Milano)-phospholipid complex
    Sanjay Kaul
    Vascular Physiology and Thrombosis Research Laboratory of the Atherosclerosis Research Center, Division of Cardiology, Cedars Sinai Medical Center, Los Angeles, California 90048, USA
    J Am Coll Cardiol 44:1311-9. 2004
    ....
  10. ncbi request reprint Trials and tribulations of non-inferiority: the ximelagatran experience
    Sanjay Kaul
    Division of Cardiology, Cedars Sinai Medical Center, and the David Geffen School of Medicine, University of California, Los Angeles, California 90048, USA
    J Am Coll Cardiol 46:1986-95. 2005
    ..Such determinations of non-inferiority are highly dependent on the underlying assumptions, and graphical sensitivity analyses make this dependence explicit...
  11. ncbi request reprint As time goes by: current status and future directions in the controversy over stenting
    Sanjay Kaul
    Division of Cardiology, Cedars Sinai Medical Center, and the David Geffen School of Medicine, University of California, Los Angeles, California 90048, USA
    J Am Coll Cardiol 50:128-37. 2007
    ....
  12. ncbi request reprint Polymeric-based perivascular delivery of a nitric oxide donor inhibits intimal thickening after balloon denudation arterial injury: role of nuclear factor-kappaB
    S Kaul
    Burns and Allen Research Institute and the Division of Cardiology, Cedars Sinai Medical Center, Los Angeles, California 90048, USA
    J Am Coll Cardiol 35:493-501. 2000
    ..To examine the effect of a polymeric-based periadventitial delivery of a nitric oxide (NO)-releasing diazeniumdiolate, spermine/NO (SPER/NO), on balloon injury-induced neointimal hyperplasia in rat ileofemoral arteries...
  13. ncbi request reprint Low molecular weight heparin in acute coronary syndrome: evidence for superior or equivalent efficacy compared with unfractionated heparin?
    S Kaul
    Department of Medicine, Cedars Sinai Medical Center, and UCLA School of Medicine, Los Angeles, California 90048, USA
    J Am Coll Cardiol 35:1699-712. 2000
    ..The logistic ease of administration without the need for monitoring anticoagulation appears to be the major advantage over UFH...
  14. doi request reprint Advances in antiplatelet treatment for acute coronary syndromes
    Shervin Eshaghian
    Division of Cardiology, Cedars Sinai Medical Center, 8700 Beverly Blvd, Los Angeles, CA 90048, USA
    Heart 96:656-61. 2010
    ....
  15. ncbi request reprint Effects of GP IIb/IIIa receptor inhibitor tirofiban (aggrastat) in ex vivo canine arteriovenous shunt model of stent thrombosis
    Vladimir Rukshin
    Department of Medicine, Cedars Sinai Medical Center and the UCLA School of Medicine, Los Angeles, California 90048, USA
    J Cardiovasc Pharmacol 41:615-24. 2003
    ..Thus, tirofiban produced a dose-dependent dethrombotic effect on stent thrombosis and inhibited acute de novo stent thrombosis under high-shear flow conditions...
  16. ncbi request reprint A prospective, nonrandomized, open-labeled pilot study investigating the use of magnesium in patients undergoing nonacute percutaneous coronary intervention with stent implantation
    Vladimir Rukshin
    Burns and Allen Research Institute, Department of Medicine, Cedars Sinai Medical Center, and UCLA School of Medicine, Los Angeles, California, USA
    J Cardiovasc Pharmacol Ther 8:193-200. 2003
    ..Magnesium has recently been shown to inhibit acute stent thrombosis in animal models. This study tested the feasibility of magnesium administration in patients undergoing nonacute percutaneous coronary intervention with stent implantation...
  17. ncbi request reprint Differential effects of apolipoprotein A-I-mimetic peptide on evolving and established atherosclerosis in apolipoprotein E-null mice
    Xiaojun Li
    Atherosclerosis Research Center, Division of Cardiology, Department of Medicine and Burns and Allen Research Institute, Cedars Sinai Medical Center and David Geffen School of Medicine at UCLA, Los Angeles, Calif 90048, USA
    Circulation 110:1701-5. 2004
    ....
  18. ncbi request reprint Role of clopidogrel in managing atherothrombotic cardiovascular disease
    Shervin Eshaghian
    Cedars Sinai Medical Center and the David Geffen School of Medicine, University of California, Los Angeles, California 90048, USA
    Ann Intern Med 146:434-41. 2007
    ....
  19. ncbi request reprint An orwellian discourse on the meaning and measurement of noninferiority
    George A Diamond
    Division of Cardiology, Cedars Sinai Medical Center, Los Angeles, California, USA
    Am J Cardiol 99:284-7. 2007
    ..In conclusion, the resultant probabilistic measures thereby render the meaning of noninferiority more transparent and clinically relevant...
  20. ncbi request reprint Dose-dependent modulation of tissue factor protein and procoagulant activity in human monocyte-derived macrophages by oxidized low density lipoprotein
    Simcha Ron Meisel
    Atherosclerosis Research Center, Division of Cardiology, Department of Medicine, The CSMC Burns and Allen Research Institute
    J Atheroscler Thromb 18:596-603. 2011
    ..In this study we tested the hypothesis that oxLDL modulates TF expression in human monocyte-derived macrophages (MDMs)...
  21. doi request reprint The JUPITER trial: myth or reality?
    Ryan P Morrissey
    Cedars Sinai Heart Institute, Cedars Sinai Medical Center, Los Angeles, CA 90048, USA
    Curr Atheroscler Rep 13:413-21. 2011
    ..Given these limitations, the attendant societal health policy implications remain largely unknown...
  22. ncbi request reprint Comparative antithrombotic effects of magnesium sulfate and the platelet glycoprotein IIb/IIIa inhibitors tirofiban and eptifibatide in a canine model of stent thrombosis
    Vladimir Rukshin
    Vascular Physiology and Thrombosis Research Laboratory of the Atherosclerosis Research Center, Cedars Sinai Burns and Allen Research Institute, Los Angeles, Calif, USA
    Circulation 105:1970-5. 2002
    ..Our objective was to compare the antithrombotic effects of the glycoprotein IIb/IIIa inhibitors tirofiban and eptifibatide with magnesium in an ex vivo canine arteriovenous shunt model of stent thrombosis...
  23. ncbi request reprint Uncertain effects of rosiglitazone on the risk for myocardial infarction and cardiovascular death
    George A Diamond
    Cedars Sinai Medical Center and David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, California, USA
    Ann Intern Med 147:578-81. 2007
    ..We conclude that the risk for myocardial infarction and death from cardiovascular disease for diabetic patients taking rosiglitazone is uncertain: Neither increased nor decreased risk is established...
  24. ncbi request reprint Narrative review: drug-eluting stents for the management of restenosis: a critical appraisal of the evidence
    Roderick Tung
    Cedars Sinai Medical Center, David Geffen School of Medicine, and University of California, Los Angeles, Los Angeles, California 90048, USA
    Ann Intern Med 144:913-9. 2006
    ....
  25. ncbi request reprint Bridging therapy in the perioperative management of patients with drug-eluting stents
    Stanley Chou
    Division of Cardiology, Cedars Sinai Medical Center, Los Angeles, CA, USA
    Rev Cardiovasc Med 10:209-18. 2009
    ....
  26. ncbi request reprint Toll-like receptor-4 is expressed by macrophages in murine and human lipid-rich atherosclerotic plaques and upregulated by oxidized LDL
    X H Xu
    Atherosclerosis Research Center, Burns and Allen Research Institute, Division of Cardiology, Steven Spielberg Pediatric Research Center, Los Angeles, California, USA
    Circulation 104:3103-8. 2001
    ..Moreover, upregulation of TLR-4 in macrophages by oxidized LDL suggests that TLR-4 may provide a potential pathophysiological link between lipids and infection/inflammation and atherosclerosis...
  27. ncbi request reprint Effects of recombinant apolipoprotein A-I(Milano) on aortic atherosclerosis in apolipoprotein E-deficient mice
    P K Shah
    Atherosclerosis Research Center, Division of Cardiology, Cedars Sinai Medical Center and UCLA School of Medicine, Los Angeles, Calif 90048, USA
    Circulation 97:780-5. 1998
    ..In this study, we tested the hypothesis that apo A-I(Milano)/PC would inhibit aortic atherosclerosis in apo E-deficient mice...
  28. ncbi request reprint COURAGE under fire: on the management of stable coronary disease
    George A Diamond
    Division of Cardiology, Cedars Sinai Medical Center, and the David Geffen School of Medicine, University of California, Los Angeles, California, USA
    J Am Coll Cardiol 50:1604-9. 2007
    ..We herein reevaluate the evidence with regard to each of these points, and conclude that COURAGE indeed provides relevant new information to assist the practitioner in the appropriate management of patients with stable coronary disease...
  29. ncbi request reprint Cardiac amyloidosis: new insights into diagnosis and management
    Shervin Eshaghian
    Division of Cardiology, Cedars Sinai Medical Center, Los Angeles, California, USA
    Rev Cardiovasc Med 8:189-99. 2007
    ..Recent advances in our understanding of the pathophysiology of amyloid have allowed the various types to be differentiated, which has led to targeted therapy for each unique pathophysiologic process...
  30. ncbi request reprint Acute myocardial infarction in human immunodeficiency virus-infected patients
    Shlomo Matetzky
    Division of Cardiology, Cedars Sinai Medical Center, 8700 Beverly Blvd, Los Angeles, CA 90048, USA
    Arch Intern Med 163:457-60. 2003
    ..Patients infected with human immunodeficiency virus (HIV) are at an increased risk for premature coronary artery disease. However, the clinical outcome of HIV-infected patients who have had an acute myocardial infarction (AMI) is unknown...
  31. doi request reprint Bayesian classification of clinical practice guidelines
    George A Diamond
    Division of Cardiology, Cedars Sinai Medical Center, and the David Geffen School of Medicine, University of California, Los Angeles, CA, USA
    Arch Intern Med 169:1431-5. 2009
    ..We conclude that this quantitative schema has the potential to improve the quality and cost of evidence-based clinical management...
  32. doi request reprint Statins in acute coronary syndromes: do the guideline recommendations match the evidence?
    Ryan P Morrissey
    Cedars Sinai Medical Center, Los Angeles, California 90048, USA
    J Am Coll Cardiol 54:1425-33. 2009
    ..On the basis of these observations, and despite a compelling pathophysiologic rationale, the justification for current Class I, Level of Evidence: A recommendation for statin therapy in patients with ACS remains open to question...
  33. ncbi request reprint The things to come of SHAPE: cost and effectiveness of cardiovascular prevention
    George A Diamond
    Division of Cardiology, Cedars Sinai Medical Center, and David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, California, USA
    Am J Cardiol 99:1013-5. 2007
    ..In conclusion, greater attention should be paid to improving the population-wide delivery of and long-term adherence to proven preventive therapy than to the identification of "high-risk" treatment targets...
  34. ncbi request reprint Prior convictions: Bayesian approaches to the analysis and interpretation of clinical megatrials
    George A Diamond
    Division of Cardiology, Cedars Sinai Medical Center, and the School of Medicine, University of California, Los Angeles, California, USA
    J Am Coll Cardiol 43:1929-39. 2004
    ..Accordingly, the Bayesian approach should be employed more widely in the design, analysis, and interpretation of clinical megatrials...
  35. ncbi request reprint Augmentation of in-stent clot dissolution by low frequency ultrasound combined with aspirin and heparin. An ex-vivo canine shunt study
    Yoram Neuman
    Vascular Physiology and Thrombosis Research Laboratory of the Atherosclerosis Research Center, Cedars Sinai Medical Center, Division of Cardiology, Room 5314, 8700 Beverly Boulevard, Los Angeles, CA 90048, USA
    Thromb Res 112:99-104. 2003
    ..Ultrasound can accelerate clot dissolution in vitro and in vivo. We used an ex vivo canine shunt to investigate low frequency ultrasound effects on platelet-rich stent thrombosis...
  36. ncbi request reprint Screen testing cardiovascular prevention in asymptomatic diabetic patients
    George A Diamond
    Division of Cardiology, Cedars Sinai Medical Center, Los Angeles, California, USA
    J Am Coll Cardiol 49:1915-7. 2007
    ..This analysis shows that unconditional treatment is the dominant strategy, costing 24% less ($3.2 billion) and preventing 25% more (16,800) atherosclerotic events annually on a national basis...
  37. ncbi request reprint Inhibition of acute stent thrombosis under high-shear flow conditions by a nitric oxide donor, DMHD/NO. An ex vivo porcine arteriovenous shunt study
    S Kaul
    Division of Cardiology, Cedars Sinai Medical Center Research Institute, Los Angeles, CA, USA
    Circulation 94:2228-34. 1996
    ..The objective of the present study was to determine whether local delivery of a new type of NO donor, the NO adduct of N,N'-dimethylhexanediamine (DMHD/NO), inhibits acute stent thrombosis (ST) at high-shear flow...
  38. ncbi request reprint Decreased neointimal thickening after arterial wall injury in inducible nitric oxide synthase knockout mice
    K Y Chyu
    Atherosclerosis Research Center, Burns and Allen Research Institute, Division of Cardiology, Cedars Sinai Medical Center, Los Angeles CA 90048, USA
    Circ Res 85:1192-8. 1999
    ..Taken together, these findings suggest that iNOS expression after vascular injury may promote neointima formation...
  39. ncbi request reprint High-dose recombinant apolipoprotein A-I(milano) mobilizes tissue cholesterol and rapidly reduces plaque lipid and macrophage content in apolipoprotein e-deficient mice. Potential implications for acute plaque stabilization
    P K Shah
    Atherosclerosis Research Center, The Division of Cardiology, Cedars Sinai Medical Center and UCLA School of Medicine, Los Angeles, Calif and Esperion Therapeutics Inc, Ann Arbor, Michigan, USA
    Circulation 103:3047-50. 2001
    ..In this study, we tested whether a single high dose of recombinant apoA-I(m) could rapidly mobilize tissue cholesterol and reduce plaque lipid and macrophage content in apoE-deficient mice...
  40. ncbi request reprint Membrane type 1 matrix metalloproteinase expression in human atherosclerotic plaques: evidence for activation by proinflammatory mediators
    T B Rajavashisth
    Atherosclerosis Research Center, Burns and Allen Research Institute, Division of Cardiology, Department of Medicine, Cedars Sinai Medical Center, Los Angeles, CA, USA
    Circulation 99:3103-9. 1999
    ....
  41. ncbi request reprint Sildenafil-nitric oxide donor combination promotes ventricular tachyarrhythmias in the swine right ventricle
    Moshe Swissa
    Division of Cardiology, Department of Medicine, Cedars Sinai Medical Center, Los Angeles 90048, USA
    Am J Physiol Heart Circ Physiol 282:H1787-92. 2002
    ..We conclude that a sildenafil (2 microg/ml) and NO donor combination increases VT/VF vulnerability in the normal RV by a mechanism compatible with the restitution hypothesis...
  42. doi request reprint Prevention of atrial fibrillation with omega-3 fatty acids: a meta-analysis of randomised clinical trials
    Tong Liu
    The Heart Institute, Cedars Sinai Medical Center, Los Angeles, CA 90048, USA
    Heart 97:1034-40. 2011
    ..Previous randomised controlled trials (RCT) regarding n-3 PUFA supplementation for atrial fibrillation (AF) prevention have yielded conflicting results...
  43. ncbi request reprint From here to eternity: a unified kinetic model for the pathophysiology of atherosclerotic events
    George A Diamond
    Division of Cardiology, Cedars Sinai Medical Center, Los Angeles, Calif, USA
    Am J Med 120:5-11. 2007
    ....
  44. doi request reprint Dronedarone for atrial fibrillation have we expanded the antiarrhythmic armamentarium?
    David Singh
    Division of Cardiology, Cedars Sinai Medical Center, and the David Geffen School of Medicine, University of California, Los Angeles, California 90048, USA
    J Am Coll Cardiol 55:1569-76. 2010
    ..We conclude that the available data support the use of dronedarone in select patient populations as a second- or third-line agent...
  45. ncbi request reprint Differentiation of adherent human monocytes into macrophages markedly enhances tissue factor protein expression and procoagulant activity
    Simcha R Meisel
    Department of Medicine, Atherosclerosis Research Center, Division of Cardiology, The Cedars Sinai Medical Center Burns and Allen Research Institute, School of Medicine, University of California, Los Angeles, CA, USA
    Atherosclerosis 161:35-43. 2002
    ..This cell-culture model may provide the opportunity to evaluate the effect of various interventions on macrophage procoagulant activity...
  46. ncbi request reprint Hazardous to your health: kinetic foundations of risk stratification and therapeutic triage
    George A Diamond
    Division of Cardiology, Cedars Sinai Medical Center, and David Geffen School of Medicine, University of California, Los Angeles, USA
    Am J Med 119:275.e1-6. 2006
    ..Clinical risk stratification nevertheless relies only on the former...
  47. doi request reprint Forbidden fruit: on the analysis of recurrent events in randomized clinical trials
    George A Diamond
    Division of Cardiology, Cedars Sinai Medical Center, Los Angeles, California University of California, Los Angeles, David Geffen School of Medicine, Los Angeles, California
    Am J Cardiol 111:1530-6. 2013
    ..The application of this approach to several previously published trials illustrates its facility to help elucidate the causal mechanisms underlying empirical demonstrations of safety and efficacy...
  48. doi request reprint On reporting of effect size in randomized clinical trials
    George A Diamond
    Division of Cardiology, Cedars Sinai Medical Center and University of California, Los Angeles, California, USA
    Am J Cardiol 111:613-7. 2013
    ..In conclusion, our results have shown that composite measures of effect size communicate the clinical importance of trial results better than do conventional assessments of risk reduction and statistical significance...
  49. ncbi request reprint By desperate appliance relieved? On the clinical relevance of risk stratification to therapeutic decision-making
    George A Diamond
    Division of Cardiology, Cedars Sinai Medical Center, David Geffen School of Medicine, University of California, Los Angeles, California
    Am J Cardiol 109:919-23. 2012
    ..Instead, risk stratification guidelines specific to a particular disease and a particular treatment should be founded on prospective empiric validation...
  50. ncbi request reprint Intravenous magnesium in experimental stent thrombosis in swine
    V Rukshin
    Thrombosis Research Laboratory of the Atherosclerosis Research Center, Burns and Allen Research Institute, Div. of Cardiology, Dept. of Medicine, Cedars-Sinai Medical Center, UCLA School of Medicine, Los Angeles, California, USA
    Arterioscler Thromb Vasc Biol 21:1544-9. 2001
    ..Thus, magnesium may be an effective agent for preventing stent thrombosis...
  51. ncbi request reprint Beneficial antithrombotic effects of the association of pharmacological oral magnesium therapy with aspirin in coronary heart disease patients
    M Shechter
    Cedars Sinai Burns and Allen Research Institute, Department of Medicine, Cedars Sinai Medical Center and the UCLA School of Medicine Los Angeles, California, USA
    Magnes Res 13:275-84. 2000
    ..These findings suggest a potential mechanism whereby magnesium may beneficially alter outcomes in patients with CAD...
  52. doi request reprint Natriuretic peptides and heart failure in the patient with chronic kidney disease: a review of current evidence
    S Dhar
    Department of Medicine, Drexel University College of Medicine, Philadelphia, Pennsylvania, USA
    Postgrad Med J 85:299-302. 2009
    ..We review the role of natriuretic peptide in heart failure in the setting of chronic renal disease...
  53. ncbi request reprint Rosiglitazone and cardiovascular risk
    George A Diamond
    N Engl J Med 357:938-9; author reply 939-40. 2007
  54. ncbi request reprint From vulnerable plaque to vulnerable patient: a call for new definitions and risk assessment strategies: Part I
    Morteza Naghavi
    The Center for Vulnerable Plaque Research, University of Texas Houston, The Texas Heart Institute, and President Bush Center for Cardiovascular Health, Memorial Hermann Hospital, Houston, USA
    Circulation 108:1664-72. 2003
    ..We encourage healthcare policy makers to promote translational research for screening and treatment of vulnerable patients...
  55. ncbi request reprint From vulnerable plaque to vulnerable patient: a call for new definitions and risk assessment strategies: Part II
    Morteza Naghavi
    The Center for Vulnerable Plaque Research, University of Texas Houston, The Texas Heart Institute, and President Bush Center for Cardiovascular Health, Memorial Hermann Hospital, Houston, USA
    Circulation 108:1772-8. 2003
    ..We encourage healthcare policy makers to promote translational research for screening and treatment of vulnerable patients...
  56. ncbi request reprint From vulnerable plaque to vulnerable patient--Part III: Executive summary of the Screening for Heart Attack Prevention and Education (SHAPE) Task Force report
    Morteza Naghavi
    Association for Eradication of Heart Attack, Houston, Texas 77005, USA
    Am J Cardiol 98:2H-15H. 2006
    ....
  57. doi request reprint Revascularization for unprotected left main stem coronary artery stenosis stenting or surgery
    David P Taggart
    Department of Cardiac Surgery, University of Oxford, John Radcliffe Hospital, Oxford, United Kingdom
    J Am Coll Cardiol 51:885-92. 2008
    ..We conclude that CABG should indeed remain the preferred revascularization treatment in good surgical candidates with unprotected LMS stenosis...
  58. ncbi request reprint Effect of exposure to cigarette smoke on carotid artery intimal thickening: the role of inducible NO synthase
    Takeo Anazawa
    Division of Cardiology and Atherosclerosis Research Center, Burns and Allen Research Institute, and the Department of Medicine, Cedars Sinai Medical Center and David Geffen School of Medicine at University of California, Los Angeles 90048, USA
    Arterioscler Thromb Vasc Biol 24:1652-8. 2004
    ..We investigated the role of inducible NO synthase (iNOS) in intimal thickening with exposure to cigarette smoke (CS)...
  59. ncbi request reprint Simvastatin with or without ezetimibe in familial hypercholesterolemia
    George A Diamond
    N Engl J Med 359:530; author reply 532. 2008